{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:26:06Z","timestamp":1740108366606,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001773","name":"University of New South Wales","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001773","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Existing recommended first-line antibiotic agents for MRSA pneumonia have several shortcomings. We reviewed 29 cases of community- and hospital-acquired MRSA pneumonia managed at our hospital. Lincosamide monotherapy was administered to 21\/29 (72%) and was the predominant antibiotic regimen (&gt;\u200950% course duration) in 19\/29 (66%). Patients receiving lincosamide-predominant monotherapy were no more likely to die or require intensive care unit admission than patients receiving vancomycin-predominant monotherapy (5\/19 (26%) versus 4\/7 (57%), <jats:italic>p<\/jats:italic>\u2009=\u20090.19); 5\/7 (71%) patients admitted to ICU and 4\/5 (80%) bacteraemic patients received lincosamide-predominant monotherapy. MRSA pneumonia can be safely treated with lincosamide monotherapy if the isolate is susceptible.<\/jats:p>","DOI":"10.1007\/s10096-024-04816-9","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T13:01:45Z","timestamp":1712926905000},"page":"1247-1250","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lincosamide monotherapy treatment of methicillin-resistant Staphylococcus aureus pneumonia in tropical Australia: a case series"],"prefix":"10.1007","volume":"43","author":[{"given":"Stuart","family":"Campbell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1423-3839","authenticated-orcid":false,"given":"Josh","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"issue":"5","key":"4816_CR1","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1183\/09031936.00041009","volume":"34","author":"KZ Vardakas","year":"2009","unstructured":"Vardakas KZ, Matthaiou DK, Falagas ME (2009) Incidence, characteristics and outcomes of patients with severe community acquired-MRSA pneumonia. Eur Respir J 34(5):1148\u20131158. https:\/\/doi.org\/10.1183\/09031936.00041009","journal-title":"Eur Respir J"},{"issue":"7","key":"4816_CR2","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","volume":"200","author":"JP Metlay","year":"2019","unstructured":"Metlay JP et al (2019) Diagnosis and treatment of adults with community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 200(7):e45\u2013e67. https:\/\/doi.org\/10.1164\/rccm.201908-1581ST","journal-title":"Am J Respir Crit Care Med"},{"key":"4816_CR3","volume-title":"The Sanford guide to antimicrobial therapy","author":"DJ Gilbert","year":"2023","unstructured":"Gilbert DJ et al (2023) The Sanford guide to antimicrobial therapy. Sperryville, USA"},{"issue":"4","key":"4816_CR4","first-page":"694","volume":"19","author":"FR Bruniera","year":"2015","unstructured":"Bruniera FR et al (2015) The use of Vancomycin with its therapeutic and adverse effects: a review. Eur Rev Med Pharmacol Sci 19(4):694\u2013700","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"6","key":"4816_CR5","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40262-022-01125-2","volume":"61","author":"E Bandin-Vilar","year":"2022","unstructured":"Bandin-Vilar E et al (2022) A review of Population pharmacokinetic analyses of Linezolid. Clin Pharmacokinet 61(6):789\u2013817. https:\/\/doi.org\/10.1007\/s40262-022-01125-2","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"4816_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/cid\/cir034","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C et al (2011) Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 52(3):285\u2013292. https:\/\/doi.org\/10.1093\/cid\/cir034","journal-title":"Clin Infect Dis"},{"issue":"11","key":"4816_CR7","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1177\/1060028019856721","volume":"53","author":"J Hong","year":"2019","unstructured":"Hong J, Ensom MHH, Lau TTY (2019) What is the evidence for co-trimoxazole, clindamycin, doxycycline, and Minocycline in the treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia? Ann Pharmacother 53(11):1153\u20131161. https:\/\/doi.org\/10.1177\/1060028019856721","journal-title":"Ann Pharmacother"},{"key":"4816_CR8","unstructured":"Directed therapy for pneumonia: staphylococcal pneumonia; Methicillin resistant S. Aureus pneumonia, in therapeutic guidelines. (2019) Therapeutic Guidelines Limited: Melbourne"},{"issue":"4","key":"4816_CR9","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.pathol.2018.11.015","volume":"51","author":"I Guthridge","year":"2019","unstructured":"Guthridge I et al (2019) Increasing prevalence of methicillin-resistant Staphylococcus aureus in remote Australian communities: implications for patients and clinicians. Pathology 51(4):428\u2013431. https:\/\/doi.org\/10.1016\/j.pathol.2018.11.015","journal-title":"Pathology"},{"issue":"9","key":"4816_CR10","doi-asserted-by":"publisher","first-page":"e0034321","DOI":"10.1128\/AAC.00343-21","volume":"65","author":"I Guthridge","year":"2021","unstructured":"Guthridge I et al (2021) Efficacy and safety of Intravenous Lincosamide Therapy in Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother 65(9):e0034321. https:\/\/doi.org\/10.1128\/AAC.00343-21","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"4816_CR11","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/cid\/ciw300","volume":"63","author":"WH Self","year":"2016","unstructured":"Self WH et al (2016) Staphylococcus aureus Community-acquired Pneumonia: prevalence, clinical characteristics, and outcomes. Clin Infect Dis 63(3):300\u2013309. https:\/\/doi.org\/10.1093\/cid\/ciw300","journal-title":"Clin Infect Dis"},{"issue":"7","key":"4816_CR12","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jama.2020.9151","volume":"325","author":"K Yadav","year":"2021","unstructured":"Yadav K, Lewis RJ (2021) Immortal Time Bias in Observational studies. JAMA 325(7):686\u2013687. https:\/\/doi.org\/10.1001\/jama.2020.9151","journal-title":"JAMA"},{"issue":"2","key":"4816_CR13","doi-asserted-by":"publisher","first-page":"e0212029","DOI":"10.1371\/journal.pone.0212029","volume":"14","author":"CP Vicetti Miguel","year":"2019","unstructured":"Vicetti Miguel CP et al (2019) A decade of antimicrobial resistance in Staphylococcus aureus: a single center experience. PLoS ONE 14(2):e0212029. https:\/\/doi.org\/10.1371\/journal.pone.0212029","journal-title":"PLoS ONE"},{"key":"4816_CR14","doi-asserted-by":"publisher","first-page":"1102779","DOI":"10.3389\/fcimb.2023.1102779","volume":"13","author":"X Wu","year":"2023","unstructured":"Wu X et al (2023) Antimicrobial resistance profile of methicillin-resistant Staphylococcus aureus isolates in children reported from the ISPED surveillance of bacterial resistance, 2016\u20132021. Front Cell Infect Microbiol 13:1102779. https:\/\/doi.org\/10.3389\/fcimb.2023.1102779","journal-title":"Front Cell Infect Microbiol"},{"key":"4816_CR15","unstructured":"Coombs G, Bell JM, Daley D, Collignon P, Cooley L, Gottlieb T, Iredell J, Warner M, and Robson J (2022) on behalf of the Australian Group on Antimicrobial Resistance and Australian Commission on Safety and Quality in Health Care. AGAR Surveillance Outcome Programs 2021 Report. ACSQHC: Sydney."}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-024-04816-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-024-04816-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-024-04816-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T14:10:15Z","timestamp":1718374215000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-024-04816-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["4816"],"URL":"https:\/\/doi.org\/10.1007\/s10096-024-04816-9","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"type":"print","value":"0934-9723"},{"type":"electronic","value":"1435-4373"}],"subject":[],"published":{"date-parts":[[2024,4,12]]},"assertion":[{"value":"19 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the FNQ Human Research Ethics Committee (AM\/2022\/QCH\/33448).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"As the data were retrospective and de-identified, the Far North Queensland Human Research Ethics Committee waived the requirement for informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}